PROKIDNEY CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.92 USD | -4.85% |
|
+50.19% | +120.22% |
| May. 10 | ProKidney Q1 Loss Unchanged From Year Earlier | MT |
| May. 10 | ProKidney Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 422.2 | 119.5 | 242.3 | - | - |
| Enterprise Value (EV) 1 | -68.09 | 119.5 | 64.71 | -68.15 | -55.85 |
| P/E ratio | -29.8 x | -3.12 x | -2.85 x | -4.97 x | -4.91 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | 0.45 x | -0.81 x | -0.4 x | 0.31 x | 0.22 x |
| EV / FCF | 0.86 x | - | -0.64 x | 0.21 x | 0.17 x |
| FCF Yield | 116% | - | -156% | 484% | 575% |
| Price to Book | -1.46 x | - | 3.48 x | 2.56 x | 3.51 x |
| Nbr of stocks (in thousands) | 61,540 | 67,137 | 63,923 | - | - |
| Reference price 2 | 6.860 | 1.780 | 3.790 | 3.790 | 3.790 |
| Announcement Date | 3/28/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA 1 | -150 | -147.7 | -162 | -218.7 | -259.6 |
| EBIT 1 | -153 | -151.5 | -166.7 | -217.3 | -252.3 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -147.2 | -159.5 | -145.9 | -222.9 | -245.8 |
| Net income 1 | -108 | -35.47 | -145.9 | -43.72 | -51.84 |
| Net margin | - | - | - | - | - |
| EPS 2 | -0.2300 | -0.5700 | -1.329 | -0.7619 | -0.7722 |
| Free Cash Flow 1 | -78.94 | - | -101 | -330 | -321 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 3/28/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | -34.79 | -29.44 | - | - | - | -23.06 | -38.97 | - | - | - | - | - |
| EBIT 1 | -35.57 | -30.24 | -40.88 | -39.82 | -46.62 | -24.21 | -40.08 | -43.14 | -46.51 | -49.11 | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -25.84 | - | -33.86 | -41.08 | -18.93 | -35.24 | -35.64 | -36.88 | -38.15 | - | - |
| Net income 1 | -11.93 | -6.487 | -9.665 | -9.118 | -10.98 | -5.701 | -9.492 | -35.64 | -36.88 | -38.15 | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1300 | -0.1100 | - | -0.1400 | -0.1800 | -0.0900 | -0.1600 | -0.3900 | -0.4050 | -0.3850 | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/14/22 | 3/28/23 | 5/11/23 | 8/10/23 | 11/14/23 | 3/22/24 | 5/10/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 490 | - | 178 | 310 | 298 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | -78.9 | - | -101 | -330 | -321 |
| ROE (net income / shareholders' equity) | - | - | -50% | -55.5% | -51.6% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | -4.700 | - | 1.090 | 1.480 | 1.080 |
| Cash Flow per Share 2 | -1.250 | - | -0.5600 | -0.5600 | - |
| Capex 1 | 1.85 | - | 50 | 200 | 200 |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/28/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.79
USD
Average target price
4.4
USD
Spread / Average Target
+16.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +120.22% | 242M | |
| +33.37% | 50.85B | |
| +1.55% | 42.82B | |
| +49.17% | 42.03B | |
| -4.22% | 29.55B | |
| +11.57% | 26.11B | |
| -21.00% | 19.13B | |
| +7.36% | 13.05B | |
| +28.30% | 12.16B | |
| +23.80% | 12.08B |
- Stock Market
- Equities
- PROK Stock
- Financials ProKidney Corp.
